Overview

We use the detailing data from one of the largest pharmaceutical firms in the country, examining the detailing patterns for both regulated and unregulated drug brands. We obtained detailing data for 27 brands of regulated molecules from the drug portfolio of one of the country’s largest companies (represented as Brands R1 to R27). Further, we also selected 27 unregulated brands (represented as Brands UR1 to UR27), that are close substitutes belonging to the same therapeutic categories as those of the chosen regulated brands. Descriptive measures and summary of results for regulated and unregulated brands are presented in tables below. . We find that 18 (of the 27 regulated brands) have significant negative LATE estimates indicating a decline in detailing efforts, whereas 15 of the 27 unregulated brands have significant positive LATE estimates.